About Autonomix Medical Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://autonomix.com/
Frequently Asked Questions
What is the 52-week range for AMIX?
The 52-week high is $32.55 and the 52-week low is $2.44.
What is the P/E ratio for AMIX?
The P/E ratio data is currently unavailable.
What is the dividend yield for AMIX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -267.73%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.76.
Analyst Recommendation Trends
Wall Street analyst consensus for AMIX over the last few months:
Latest AMIX News
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion
Autonomix Medical Completes Pre-Submission Meeting With FDA For Its Transvascular Sensing Platform
Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled "Systems for Assessing Neural Activity in an Eye." Th
Autonomix Medical Receives European Patent Titled Systems For Assessing Neural Activity In An Eye
Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Autonomix Medical, Inc. Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to a
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-03 | Smith Trent N. | +15,000 | - | - |
| 2026-09-03 | KLEMP WALTER V | +13,000 | - | - |
| 2026-09-03 | Bisson Lori | +13,000 | - | - |
| 2026-09-03 | Hauser Bradley | +27,000 | - | - |